Dollar General (DG) marked its 27th consecutive year of same-store sales growth in fiscal 2016. It followed this milestone up with a beat on both the top and bottom lines during its first quarter of 2017, with comps once again growing – but by only about 0.7%. As I was sifting through the retail carnage, Dollar General was one of the companies that stood out as above average, so I decided to take a closer look with this article.
The company’s primary niche seems to come from its low cost operating structure. The majority of its stores are rural, with roughly 70% of them located in towns of 20,000 people or less. It constantly seeks ways to reduce (or at least control) costs that won’t affect the shopping experience for its customers, many of whom are primarily in a lower income bracket. This is exhibited by its low prices, where 80% of its stock-keeping units are set at $5 or less.
Source: 2016 10-K
Best Low Price Stocks To Buy Right Now: Golar LNG Partners LP(GMLP)
- [By Roberto Pedone]
Golar LNG Partners LP (GMLP), a limited partnership, owns and operates floating storage and regasification units and LNG carriers under long-term charters. This stock closed up 3.5% at $32.74 in Monday’s trading session.
Monday’s Volume: 432,000
Three-Month Average Volume: 81,559
Volume % Change: 283%
From a technical perspective, GMLP bounced notably higher here right off its 200-day moving average of $31.79 and back above its 50-day moving average of $32.56 with strong upside volume. This move is quickly pushing shares of GMLP within range of triggering a near-term breakout trade. That trade will hit if GMLP manages to take out Monday’s intraday high at $32.96 to some more near-term overhead resistance at $33.15 with high volume.
Traders should now look for long-biased trades in GMLP as long as it’s trending above its 200-day at $31.79 and then once it sustains a move or close above those breakout levels with volume that’s near or above 81,559 shares. If that breakout hits soon, then GMLP will set up to re-test or possibly take out its next major overhead resistance levels at $34.78 to its 52-week high at $36.
Best Low Price Stocks To Buy Right Now: Roche Holding AG (RHHBY)
- [By SEEKINGALPHA.COM]
AbbVie (ABBV) reported positive trial data from its phase 3 study of venetoclax in combination with Roches (OTCQX:RHHBY) Rituxan in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and showed the venetoclax combo extended progression-free survival compared to bendamustine + Rituxan. I recently covered AbbVie and its pipeline and argued that AbbVie has little to replace Humira with in that pipeline.
- [By Keith Speights]
Eisai (NASDAQOTH:ESALY), Novo Nordisk (NYSE:NVO), and Roche Holding Ltd. (NASDAQOTH:RHHBY) fit that description well. Each of these companies markets obesity drugs, but each also sells a broad array of other products with multiple pipeline candidates potentially on the way. Here’s why Eisai, Novo Nordisk, and Roche rank as the three best obesity-drug stocks to buy in 2017.
- [By SEEKINGALPHA.COM]
Let me first review yesterday’s positive interim Phase 2 results for AIR DNase (alidornase alfa) to treat cystic fibrosis. This phase of the trial was a 28-day switch-over study in cystic fibrosis patients who were previously treated with Roche’s (OTCQX:RHHBY) Pulmozyme (dornase alfa).
- [By WWW.KIPLINGER.COM]
EFAV is another low-volatility product, this one centered around the MSCI EAFE Index, an ex-U.S./Canada index that includes companies in developed markets across Europe, Australasia and the Far East. EFAV uses Barras multi-factor risk model to weed out the riskiest MSCI EAFE Index stocks, resulting in a current 230-stock low-vol portfolio stuffed with stable blue chips. Stocks like multinational foods giant Nestle SA (NSRGY) and healthcare giant Roche Holding Ltd. (RHHBY) line EFAVs top holdings, and help throw off a decent yield of about 2.5%.
- [By SEEKINGALPHA.COM]
Current biologic top sellers in RA include AbbVie (NYSE:ABBV), Johnson & Johnson (NYSE:JNJ), Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Roche (OTCQX:RHHBY), and UCB (OTCPK:UCBJF). The table below shows the drugs marketed by these pharmaceutical giants and relevant details:
- [By WWW.THESTREET.COM]
Novartis AG (NVS) said Monday that it has received approval from the European Commission for a blood cancer treatment known as Rixathon, a biosimilar version of Roche AG’s (RHHBY) blockbuster Rituxan that generated around $7.5 billion in sales last year.
Best Low Price Stocks To Buy Right Now: Inter Parfums, Inc.(IPAR)
- [By Monica Gerson]
Inter Parfums, Inc. (NASDAQ: IPAR) is estimated to post its quarterly earnings at $0.31 per share on revenue of $110.58 million.
Norwegian Cruise Line Holdings Ltd (NASDAQ: NCLH) is expected to report its quarterly earnings at $0.37 per share on revenue of $1.10 billion.